MAY 20, 2013 08:00 AM PDT

Monitoring Heparin in the Clinical Laboratory

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Associate Professor, College of Medicine Department of Pathology, Immunology and Laboratory Medicine, University of Florida
    Biography
      Dr. Neil S. Harris is board-certified in anatomic and clinical pathology, as well as clinical chemistry through the American Board of Clinical Chemistry. He is currently the director of the core (chemistry/hematology) laboratory, in addition to being a clinical associate professor at the Department of Pathology, Immunology and Laboratory Medicine within the University of Florida's College of Medicine. Dr. Harris received his undergraduate and medical education at the University of Cape Town in South Africa. In the 1980s, his postgraduate training included a residency in clinical pathology (chemical pathology & immunology) in the Division of Pathology at the University of Cape Town. This was followed by a research fellowship in the Division of Hematology/Oncology and a fellowship in clinical chemistry at the Department of Laboratory Medicine at the Children's Hospital in Boston, Massachusetts. He obtained his USA credentials in pathology by completing his residency at Fletcher Allen Health Care in at the University of Vermont in Burlington.

    Abstract:

    Unfractionated heparin (UFH, commonly called heparin) is an indirect anticoagulant commonly administered prophylactically to inpatients at risk of thrombosis.  Anticoagulants, including UFH, are considered high alert medications when used for treatment. As such, assays monitoring levels of UFH are extremely important to avoid adverse effects for patients. This activity will provide improved understanding for clinicians and laboratorians related to the monitoring of UFH and related forms of heparin.  Emphasis will be placed on the role of the chromogenic anti-Xa assay as a measure of heparin activity along with clinical scenarios and outcomes studies.

    • Describe the biochemical nature of heparin including low molecular weight heparin (LMWH) and ultra-low molecular weight synthetic forms such as fondaparinux.
    • Review the anticoagulant mechanism of action of these various forms of heparin.
    • Compare the activated PTT and the anti-Xa assay as a means of monitoring heparin.
    • Explain the role of ATIII supplementation in the anti-Xa assay and its consequences.
    • Discuss the clinical consequences of anti-Xa monitoring in the context of clinical scenarios.

    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    OCT 02, 2019 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    MAR 26, 2019 02:00 PM PDT
    C.E. CREDITS
    MAR 26, 2019 02:00 PM PDT
    DATE:  March 26, 2019TIME:  2:00pm PDT, 5:00pm EDT  Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
    Loading Comments...
    Show Resources